• Something wrong with this record ?

"Definitivní léčba" pomocí centrifugální pumpy jako podpory funkce levé komory: výběr pacientů a výsledky léčby
[Destination therapy with left ventricular assist devices: patient selection and outcomes]

Mark S. Slaughter, Anna L. Meyer, Emma J. Birks

. 2011 ; 4 (3) : 49-53.

Language Czech Country Czech Republic

Document type Review

Persistent link   https://www.medvik.cz/link/bmc12000979

Destination therapy with a left ventricular assist device (LVAD) has the potential to effectively treat a large number of patients with advanced heart failure who are not eligible for heart transplantation. With the advent of continuous-flow LVADs, safe and effective long-term circulatory support is available for properly identified candidates. RECENT FINDINGS: The highest mortality following LVAD implant is observed in the sickest patients (INTERMACS profile 1); therefore, there is an increasing trend toward selecting patients with INTERMACS profiles 2-5. The less-ill patients will be studied in the planned REVIVE-IT trial. The Heart Failure Survival Score, Seattle Heart Failure Model, and Destination Therapy Risk Score may provide guidance for patient selection and preoperative optimization therapy, but these tools need to be updated for current LVAD technology. The current 1-year survival rate for patients supported for destination therapy with a continuous-flow LVAD is 74%, which represents an increase of 6% since the clinical trial was completed 2 years ago. SUMMARY: Substantial progress has been made concerning survival and quality of life since destination therapy was first introduced 10 years ago. Advances in patient selection, improved LVAD technology, and optimized treatment strategies provide much optimism for the treatment of more heart failure patients in the future.

Destination therapy with left ventricular assist devices: patient selection and outcomes

Obsahuje 1 tabulku

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc12000979
003      
CZ-PrNML
005      
20120312112918.0
007      
ta
008      
120118s2011 xr d f 000 0cze||
009      
AR
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Slaughter, Mark S. $u Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky, USA
245    11
$a "Definitivní léčba" pomocí centrifugální pumpy jako podpory funkce levé komory: výběr pacientů a výsledky léčby / $c Mark S. Slaughter, Anna L. Meyer, Emma J. Birks
246    31
$a Destination therapy with left ventricular assist devices: patient selection and outcomes
500    __
$a Obsahuje 1 tabulku
504    __
$a Literatura $b 31
520    9_
$a Destination therapy with a left ventricular assist device (LVAD) has the potential to effectively treat a large number of patients with advanced heart failure who are not eligible for heart transplantation. With the advent of continuous-flow LVADs, safe and effective long-term circulatory support is available for properly identified candidates. RECENT FINDINGS: The highest mortality following LVAD implant is observed in the sickest patients (INTERMACS profile 1); therefore, there is an increasing trend toward selecting patients with INTERMACS profiles 2-5. The less-ill patients will be studied in the planned REVIVE-IT trial. The Heart Failure Survival Score, Seattle Heart Failure Model, and Destination Therapy Risk Score may provide guidance for patient selection and preoperative optimization therapy, but these tools need to be updated for current LVAD technology. The current 1-year survival rate for patients supported for destination therapy with a continuous-flow LVAD is 74%, which represents an increase of 6% since the clinical trial was completed 2 years ago. SUMMARY: Substantial progress has been made concerning survival and quality of life since destination therapy was first introduced 10 years ago. Advances in patient selection, improved LVAD technology, and optimized treatment strategies provide much optimism for the treatment of more heart failure patients in the future.
650    _2
$a progrese nemoci $7 D018450
650    _2
$a srdeční selhání $x mortalita $x terapie $7 D006333
650    _2
$a srdeční komory $7 D006352
650    _2
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a výběr pacientů $7 D018579
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a přehledy $7 D016454
700    1_
$a Meyer, Anna L. $u Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky, USA
700    1_
$a Birks, Emma J. $u Division of Cardiovascular medicine, University od Lousville, Lousville, Kentucky, USA
773    0_
$t Current opinion in cardiology $x 1802-3711 $g Roč. 4, č. 3 (2011), s. 49-53 $w MED00156016
910    __
$a ABA008 $b B 2480 $c 414 $y 2
990    __
$a 20120118084113 $b ABA008
991    __
$a 20120312112851 $b ABA008
999    __
$a ok $b bmc $g 893692 $s 757678
BAS    __
$a 3
BMC    __
$a 2011 $b 4 $c 3 $d 49-53 $i 1802-3711 $m Current opinion in cardiology (České vyd.) $n Curr. Opin. Cardiol. (Čes. vyd.) $x MED00156016
LZP    __
$a 2012-02/mkme

Find record

Citation metrics

Archiving options